Published in Stat Biopharm Res on January 01, 2009
Multiple test procedures for dose finding. Biometrics (1996) 2.01
Testing for the existence of a desirable dose combination. Biometrics (1993) 1.10
Closure procedures for monotone bi-factorial dose-response designs. Biometrics (2005) 1.03
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci (2003) 4.86
Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia. Am J Psychiatry (2008) 3.16
The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology (2005) 2.37
Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci (2005) 2.18
Reduced dendritic spine density in auditory cortex of subjects with schizophrenia. Neuropsychopharmacology (2008) 1.93
Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry (2011) 1.91
Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex (2002) 1.77
Lamina-specific reductions in dendritic spine density in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry (2005) 1.61
Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry (2007) 1.57
Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia. Neuropsychopharmacology (2002) 1.55
Anatomical evidence of impaired feedforward auditory processing in schizophrenia. Biol Psychiatry (2006) 1.47
Repeated Δ9-tetrahydrocannabinol exposure in adolescent monkeys: persistent effects selective for spatial working memory. Am J Psychiatry (2014) 1.44
Pyramidal cell size reduction in schizophrenia: evidence for involvement of auditory feedforward circuits. Biol Psychiatry (2004) 1.43
Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology (2006) 1.20
Primary visual cortex volume and total neuron number are reduced in schizophrenia. J Comp Neurol (2007) 1.05
Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types. J Comp Neurol (2004) 1.00
Volume and neuron number of the lateral geniculate nucleus in schizophrenia and mood disorders. Acta Neuropathol (2008) 0.94
Estimating times of surgeries with two component procedures: comparison of the lognormal and normal models. Anesthesiology (2003) 0.92
Increased expression of Kalirin-9 in the auditory cortex of schizophrenia subjects: its role in dendritic pathology. Neurobiol Dis (2011) 0.92
Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor. Biol Psychiatry (2005) 0.91
Pyramidal neuron number in layer 3 of primary auditory cortex of subjects with schizophrenia. Brain Res (2009) 0.86
Delay- and dose-dependent effects of Δ⁹-tetrahydrocannabinol administration on spatial and object working memory tasks in adolescent rhesus monkeys. Neuropsychopharmacology (2012) 0.85
Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia. Biol Psychiatry (2012) 0.84
Fully automated common carotid artery and internal jugular vein identification and tracking using B-mode ultrasound. IEEE Trans Biomed Eng (2009) 0.83
Ultrastructural localization of high-affinity choline transporter in the rat anteroventral thalamus and ventral tegmental area: differences in axon morphology and transporter distribution. J Comp Neurol (2010) 0.82
Intracortical excitatory and thalamocortical boutons are intact in primary auditory cortex in schizophrenia. Schizophr Res (2013) 0.81
Simultaneous confidence bands for comparisons to placebo, with application to detecting the minimum effective dose. J Biopharm Stat (2012) 0.80
Somal size of immunolabeled pyramidal cells in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry (2006) 0.79
Drop-the-Losers Design: Binomial Case. Comput Stat Data Anal (2009) 0.78
A meta-analytic approach to an integrated summary of efficacy: a case study of becaplermin gel. Control Clin Trials (2002) 0.78
Chronic desipramine treatment alters tyrosine hydroxylase but not norepinephrine transporter immunoreactivity in norepinephrine axons in the rat prefrontal cortex. Int J Neuropsychopharmacol (2011) 0.77
A model for repeated clustered data with informative cluster sizes. Stat Med (2013) 0.75
Adjusting for matching and covariates in linear discriminant analysis. Biostatistics (2013) 0.75
Mixture modeling with applications in schizophrenia research. Comput Stat Data Anal (2009) 0.75
Expected loss functions as additional measures to assess performance of multiple testing procedures for combination drug dose finding. Pharm Stat (2012) 0.75
An adaptive two-stage dose-response design method for establishing proof of concept. J Biopharm Stat (2013) 0.75
A framework for two-stage adaptive procedures to simultaneously test non-inferiority and superiority. Stat Med (2005) 0.75
Multivariate bernoulli mixture models with application to postmortem tissue studies in schizophrenia. Biometrics (2007) 0.75
Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension. J Rheumatol (2011) 0.75